Biotech Lock Up Expiration Hell Portfolio: Wave II Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Lock Up Expiration Hell Portfolio: Wave II

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who started this subject	4/6/2004 4:24:39 PM
From: michael_f_murphy	of 107

Metabasis Therapeutics, Inc. (NASDAQ: MBRX Proposed) We are a biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule drugs principally to treat liver diseases and metabolic diseases linked to pathways in the liver. Examples of common metabolic diseases include diabetes, hyperlipidemia, a disease involving elevated levels of lipids such as cholesterol, and obesity. Since we became an independent company in 1999, we have established a broad and growing product pipeline targeting large markets with significant unmet medical needs. We currently have three internally discovered product candidates in clinical trials indicated for the treatment of type 2 diabetes, hepatitis B and primary liver cancer. Subject 54865

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next